Novo Nordisk & Hims & Hers Health

Novo Nordisk: Novo Nordisk terminated its partnership with Hims & Hers Health due to the latter's deceptive promotion of 'knockoff' versions of Wegovy, protecting its brand and patient safety.

Hims & Hers Health: Hims & Hers Health is facing multiple class-action lawsuits for alleged securities fraud, stemming from its deceptive promotion of compounded semaglutide and the subsequent termination of its partnership with Novo Nordisk. Its stock price fell over 34% on the news.

Hims & Hers Health: Hims & Hers Health is facing a class action lawsuit for allegedly making false and misleading statements regarding its business practices, specifically the deceptive promotion and selling of 'knockoff' versions of Semaglutide®, which could lead to the termination of its collaboration with Novo Nordisk.

Hims & Hers Health: Hims & Hers Health dropped its plan to offer a compounded version of Wegovy after the FDA threatened action, leading to a 14% drop in its stock. This decision impacts its strategy in the weight-loss medication market.

Hims & Hers Health: Hims & Hers Health launched a cheaper, off-brand version of Semaglutide, capitalizing on the demand for GLP-1 drugs, which led to legal threats from Novo Nordisk.

Hims & Hers Health: Hims & Hers Health is advertising its GLP-1 weight loss drugs, emphasizing access to healthcare, and participating in the health and telehealth advertising trend.